News

Dec 30, 2021

Mabwell Announced the First Person Dosed in the Phase I Study of First Anti-ST2 Antibody in China

➞

Dec 30, 2021

Honorary Qualification | Mabwell awarded as "Excellent Case" of Shanghai Industrial Talent Team Construction 2021

➞

Dec 22, 2021

The New Drug Application of Mabwell's Denosumab Injection Biosimilars 9MW0311 Was Accepted

➞

Dec 22, 2021

The New Drug Application of Mabwell's Denosumab Injection Biosimilars 9MW0321 Was Accepted

➞

Oct 19, 2021

China's First Anti-Nectin-4 ADC Drug Receives IND Approval

➞

Oct 13, 2021

Honorary Qualification│Mabwell awarded the BIGStar 2021 Chinese Most Promising Innovative Biopharmaceutical Enterprises

➞

Sep 27, 2021

Mabwell Announced the First Patient Dosed in the Phase I Study of CD47/PD-L1 Bispecific Antibody

➞

Sep 17, 2021

Strive to Strengthen the Innovation Engine and Create a New Highland of Independent Innovation! Hang Yingwei, Director of Pudong New Area, and his team went to Mabwell for Investigation & Research

➞

Sep 06, 2021

The Taizhou Antibody Industrial Base of Mabwell Successfully Passed the EU QP Audit

➞

Aug 26, 2021

Mabwell and FEGO Reached Cooperation Agreement on the Commercialization of a Proposed Biosimilar of Adalimumab

➞